Technology

Our disruptive technology delivers a soluble, Ph neutral, fast acting powder-form drug formulation which has been developed by using our patented methodology, and “trade secret” process.

Aspire’s sublingual dose form avoids the harms of various drug therapies while maintaining or enhancing benefits. These results come from a new mechanism of action (absorption pathway) which allows for instant sublingual absorption in the mouth.

The speed of absorption and level of absorption due to our new mechanism of action into the blood stream is significant. Aspire’s sublingual dose form avoids the harms of various drug therapies while maintaining or enhancing benefits. It avoids direct damage to mucus secreting Goblet cells lining the GI track and avoids bioavailability reduction by first pass hepatic metabolism.

Aspire formula

Water Soluble
Our products dissolve quickly and easily

Perfects Dosage Management
Drugs do not pass through the liver and are not
metabolized

Ph Neutral
Will not disturb your body’s Ph balance.

Bypasses the Digestive Tract
Eliminates adverse reactions in the gastrointestinal tract

Fast Acting
Powder-form medication developed using our patented formula

Instaprin
Our first product Instaprin is soon to be released to the public.

Our technology can be applied to any number of proven, approved, “do no harm” drugs. The list below are just a few examples, but there are undoubtedly many more.

- Analgesics – global analgesics market (including Opioids) valued approximately $77.0 billion in 2021 and is projected to grow at a 5% CAGR and reach to roughly $103.0 billion by 2028

- Erectile Dysfunction (ED) – global ED market valued approximately $3.6 billion in 2021 and is projected to grow at a 6.9% CAGR and reach to roughly $5.9 billion by 2028

- Traumatic Brain Injury (TBI) – global N-acetylcysteine (NAC) market was valued at $1.1 billion in 2021 and is projected to grow at a 21.5% CAGR and attain a market value of $4.2 billion by 2028

Aspire Biopharma, Inc. has developed a disruptive technology that is a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time.

Aspire’s launch product, Instaprin, will be an aspirin formulation which addresses cardiology and stroke emergencies, acute pain management and anti-inflammatory needs.

Benefits of “instant absorption” aspirin are: to stop heart attack and stroke; allow high dose absorption for pain management including quick headache relief, post surgery, cancer pain management, and general pain relief.

Instaprin is also targeted to be a safe and effective Opioid alternative.

We are currently in discussions with regulatory bodies to “Fast Track” Instaprin, a “do no harm” aspirin medication through the FDA and regulatory agencies to leverage the issues of the current anti-opioid initiatives.